<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthases (NOS) catalyze to produce nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) from <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The isoform of NOS i.e. inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthases (iNOS) expression is observed in various human <z:mp ids='MP_0002018'>malignant tumors</z:mp> such as breast, lung, prostate and bladder, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Also an increased level of iNOS expression and activity has been found in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells of gynecological <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, stroma of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells of <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Because of its importance in causing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, iNOS enzyme has become a new target in finding novel inhibitors as anti <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> agents </plain></SENT>
<SENT sid="4" pm="."><plain>The present work focuses on the molecular docking analysis of <z:chebi fb="0" ids="16243">quercetin</z:chebi> and its analogues against iNOS enzyme </plain></SENT>
<SENT sid="5" pm="."><plain>Earlier there are reports of <z:chebi fb="0" ids="16243">quercetin</z:chebi> inhibiting iNOS enzyme in certain experiments as anti <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> agent </plain></SENT>
<SENT sid="6" pm="."><plain>But the clinical use of <z:chebi fb="0" ids="16243">quercetin</z:chebi> is limited by its low oral bioavailability and therefore needed its molecular modification to improve its pharmacological properties </plain></SENT>
<SENT sid="7" pm="."><plain>In the present study ten analogues of <z:chebi fb="0" ids="16243">quercetin</z:chebi> were found to be docked at the active site cavity with favorable ligand-protein molecular interaction and interestingly from the ADME-Toxicity analysis these analogues have enhanced pharmacological properties than <z:chebi fb="0" ids="16243">quercetin</z:chebi> </plain></SENT>
</text></document>